BACKGROUND Recurrent vasovagal syncope poses a risk because of fainting while driving, but prospective, bench-
with the Risk of Harm formula of the Canadian Cardiovascular Society (CCS) (12) . The benchmark risk of harm from this formula has not been tested against contemporary societal tolerance of harm.
The purpose of this study was to use prospectively collected data to assess the risk of syncope and driving in a high-risk population of patients with vasovagal syncope. From these data we estimated the likelihood of syncope while driving, and derived the risk of a serious motor vehicle accident. We then compared these with historical benchmarking and contemporary motor vehicle accident data from the United States, United Kingdom, and Canada.
METHODS
STUDY SUBJECTS. The subjects were participants in the POST (Prevention of Syncope Trial)-1 (13) and -2 (14) . Both trials were randomized, placebo-controlled, double-blind trials. POST-1 and POST-2 assessed the effects of beta-blockers and fludrocortisone, respectively, comparing with placebo in preventing vasovagal syncope. All involved institutional ethics committees approved both studies. POST-1 was reported in 2005, and POST-2 is registered with www.
controlled-trials.com (ISRCTN51802652) and www.
clinical-trials.gov (NCT00118482). Neither trial demonstrated significant benefit compared with placebo, although trends to benefit were noted. Patients were eligible for POST-1 if they had a positive response to standard tilt test protocols and $3 lifetime syncopal spells, and were eligible for POST-2 if they had vasovagal syncope according to the Calgary Syncope Score (15) and $3 lifetime syncopal spells. Advice on driving restrictions was left to local physicians, and compliance was not monitored. Driving guidelines and regulations differ among jurisdictions, adherence to driving guidelines by physicians is likely to be incomplete (16, 17) , and compliance by patients is unknown (5).
DATA EXTRACTION. Both POST-1 and POST-2 followed patients for up to a year. We reviewed all case report forms for syncope as an outcome. Outcomes adjudication committees reviewed all outcomes for syncopal spells. These forms contain checklists and narrative fields, all of which were reviewed for syncope while in or on a moving, wheeled vehicle. The likelihood of vasovagal syncope while operating a moving motor vehicle was computed on a per patientyear and per-faint basis. Outcome forms were also reviewed for motor vehicle accidents and for bodily injury and fatalities.
PUBLISHED REPORTS. To identify previous reports of the risk of fainting and driving we searched PubMed using these terms: driving AND syncope, drive AND faint, motor vehicle accident AND syncope, motor vehicle accident AND faint. We included papers that reported the total observation period of the population studied, the number of faints while driving, and that specified the population consisted of patients with vasovagal syncope.
STATISTICAL ANALYSIS. Continuous data were summarized as mean AE SD or median (interquartile range), and categorical data as counts (percentage).
The rate of events (fainting while driving per year) was computed based on occurrence of events over total follow-up time (years per person). Timedependent events were displayed using KaplanMeier survival analysis. To obtain current implied societal tolerances for accidents causing injury or death, we searched the Internet for data on motor vehicle accident rates and serious injury in the United Kingdom, United States, and Canada.
RESULTS
SUBJECT POPULATION. A total of 418 patients with vasovagal syncope were enrolled and followed for up to 1 year. The mean age at study enrollment was 
Syncope Risk While Driving A P R I L 2 0 1 6 : 2 0 3 -8 38 AE 17 years, and the mean onset age of vasovagal syncope was 22 AE 16 years. The subjects had a median of 10 lifetime faints and a median of 3 faints in the previous year ( Table 1 No patients drove commercial vehicles. Thus 0.48% subjects fainted while driving, and the probability of syncope while driving (the empirically derived TD Â SCI) was 0.62% per person-year ( Table 2) . Multiplying this by (V Â AC), the estimated RH was 0.0035% per person-year, less than the CCS benchmark of 0.005%.
Similarly the estimated RH per faint was 0.0018%.
One patient had prodromal symptoms while driving before fainting, and safely drove to the roadside before fainting. A second subject had no prodromal symptoms and had a minor accident with no injury to anyone involved.
REPORTS OF SYNCOPE WHILE DRIVING. The systematic search detected 444 publications. A review of titles eliminated 432 based on duplication and lack of relevance. A full review of the text narrowed the sample to 3 reports (8, 10, 18) . Table 3 summarizes the likelihood of syncope while driving from these reports and our current data. In total, 9 subjects fainted while driving during a total observation period of 2,945 years, with a likelihood of 0.31% faints while driving per driving-year. From this we estimate a risk of an accident causing injury or death of #0.0017% per driving year, less than the CCS benchmark of 0.005%. Taken together, we estimate the risks of death, and Total faints in study 615
Values are n, mean AE SD, or median (interquartile ranges). The risk of harm according to the CCS Guidelines is (probability of fainting while driving per year) Â 0.02 Â 0.28.
CCS ¼ Canadian Cardiovascular Society; POST ¼ Prevention of Syncope Trial.
Tan et al. The guidelines are intended to reduce the likelihood of an accident resulting in serious injury or death to <0.005% per driver-year. To do this, the risk of syncope during driving must be less than 1% per year, and our pooled estimate of syncope during driving ( The rates are expressed as likelihood of event per 100 driver-years, denoted as %.
est ¼ estimated; exc ¼ excluding; MVA ¼ motor vehicle accident; NR ¼ not reported; other abbreviation as in Table 2 .
Tan et al.
Syncope Risk While Driving A P R I L 2 0 1 6 : 2 0 3 -8 faints while sitting, or who faint in unique or avoidable circumstances are restricted less, whereas those who faint while sitting and without a prodrome are urged to adhere scrupulously to the guidelines. This is a difficult part of practice, and although accidents are uncommon, they do occur. All physicians should know and adhere to local guidelines and legislation.
STUDY LIMITATIONS. Although this analysis was based on POST-1 and POST-2, they were not designed to evaluate the risk of syncope during driving. Patients were followed for only 1 year, although this seems a reasonable horizon for driving advice. We do not have the data on how many patients in both trials did have a private vehicle driving license, and this potentially would underestimate the risk of harm.
However, only 5 of 418 subjects were less than 18 years old, and almost all adults have private driving licenses. Furthermore, there were few patients >70 years old in the studies, and therefore our findings cannot be extrapolated to these older patients. We also do not know the advice offered by physicians and whether it adhered with guidelines.
It may be that physician adherence to restrictive guidelines was very low (16, 17) .
We are also unable to determine the compliance of patients after receiving advice about driving restrictions, and how many refrained from driving.
Indeed, patient compliance with restrictive guidelines may be low (5). If high-risk patients in particular stopped driving, this could lower the overall estimate of risk. However, the 4 estimates are similar, and they reflect real-world outcomes based on patient populations, local policies and laws, physician advice, and patient adherence. Self-selection by some patients is to be expected, and is included in the overall estimates.
We relied on patient self-reporting of syncope and accidents. However, this was done in a research setting, and privacy was ensured as part of participation in the study. As well, self-reporting was used in all similar studies that are reported in Table 3 . Similarly,
we have no systematic data on the restrictions that might have been imposed on the subjects. Again, this is a common feature of the similar studies in Table 3 . 
